Apr 30 |
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
|
Mar 20 |
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 19 |
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
|
Mar 8 |
Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript
|
Mar 7 |
Earnings Scheduled For March 7, 2024
|
Mar 6 |
A Preview Of Alimera Sciences's Earnings
|
Feb 29 |
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update
|
Feb 8 |
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
|
Jan 4 |
Alimera Completes Recruitment for the Synchronicity Study
|
Jan 2 |
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|